구조모아 (StructureMoa)항암 chemical structure spider web
방문Sung-Soo Park
IMiD treatment(Sung-Soo Park)은 FRα 표적 세포·유전자 치료로, Multiple Myeloma, Relapsed; Multiple Myeloma (MM) 영역에서 개발·상용화 중입니다. 작용기전: that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cerebl. 전임상 단계입니다. 선택한 코호트에서 보고된 효능: ORR 26.2% (ClinicalTrials.gov NCT02336815). 차별점: first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
FRα
Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Recruiting
2026-07-13
Data Confidence · Medium
Development Signal · Watch
bispecific antibodies, and chimeric antigen receptor T cells)
first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t
that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which
immune-mediated inflammatory diseases
apoptosis, which was associated with decreased IRF4, c-Myc, and phosphorylated STAT3 levels as well as enhanced SOCS3 expression
biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop
resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators
구조화 데이터
ration of TNG961 regresses FOCAD-negative xenograft
mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Sung-Soo Park
IMiD treatment(Sung-Soo Park)은 FRα 표적 세포·유전자 치료로, Multiple Myeloma, Relapsed; Multiple Myeloma (MM) 영역에서 개발·상용화 중입니다. 작용기전: that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cerebl. 전임상 단계입니다. 선택한 코호트에서 보고된 효능: ORR 26.2% (ClinicalTrials.gov NCT02336815). 차별점: first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
FRα
Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Recruiting
2026-07-13
Data Confidence · Medium
Development Signal · Watch
bispecific antibodies, and chimeric antigen receptor T cells)
first-in-class IRAK4 heterobifunctional degrader that utilizes cereblon (CRBN) for E3 ligase recruitment and was rationally designed t
that likely involves a tightly coordinated regulation of CRBN with endothelial cell targets and highlight the need to further elucidate the mechanism(s), which could include cereblon-independent pathways, through which
immune-mediated inflammatory diseases
apoptosis, which was associated with decreased IRF4, c-Myc, and phosphorylated STAT3 levels as well as enhanced SOCS3 expression
biomarkers of Mtb burden or Mtb clearance in patients with different TB status and different risk to develop
resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators
구조화 데이터
ration of TNG961 regresses FOCAD-negative xenograft
mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.